Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) EBIT (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of EBIT readings, the most recent being -$2.1 million for Q1 2026.

  • On a quarterly basis, EBIT rose 21.61% to -$2.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$7.1 million, a 7.39% decrease, with the full-year FY2025 number at -$4.2 million, up 64.45% from a year prior.
  • EBIT hit -$2.1 million in Q1 2026 for Neuroone Medical Technologies, down from -$1.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.7 million in Q4 2024 to a low of -$3.5 million in Q2 2023.
  • Median EBIT over the past 5 years was -$2.8 million (2022), compared with a mean of -$2.3 million.
  • Biggest five-year swings in EBIT: surged 150.47% in 2024 and later crashed 199.77% in 2025.
  • Neuroone Medical Technologies' EBIT stood at -$1.8 million in 2022, then plummeted by 90.01% to -$3.4 million in 2023, then surged by 150.47% to $1.7 million in 2024, then crashed by 199.77% to -$1.7 million in 2025, then decreased by 23.05% to -$2.1 million in 2026.
  • The last three reported values for EBIT were -$2.1 million (Q1 2026), -$1.7 million (Q4 2025), and -$1.4 million (Q3 2025) per Business Quant data.